HYML-122

N/A

Report date: 2022/05/11 12:47:26
NME

Base Information

Drug NameHYML-122
Drug Alias NameHYML-122CHMFL-FLT3-122
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHefei Academy Of Physical Sciences, Chinese Academy Of SciencesHefei Cosource Pharmaceuticals
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTarapeutics Science IncHefei Academy Of Physical Sciences, Chinese Academy Of SciencesHefei Cosource Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A